BEST Overview

Upcoming Presentations: Neurotronic, Inc. will present groundbreaking results from the NECTAR III and NECTAR IV trials at TCT 2025, showcasing the first clinical outcomes of the Neuviant™ Multi-organ Denervation system for treating type 2 diabetes and hypertension.

Study Details: The trials evaluated the safety and efficacy of hepatic and renal denervation in patients with uncontrolled type 2 diabetes and hypertension, with presentations scheduled for October 26 and 27, 2025, in San Francisco.

Innovative Therapy: The Neuviant MDN procedure involves delivering ethanol via catheter to disrupt overactive sympathetic nerve pathways, aiming to lower blood sugar and blood pressure in patients.

Company Background: Founded in 2015, Neurotronic focuses on pioneering multi-organ denervation therapies for complex cardiovascular and metabolic diseases, including type 2 diabetes and hypertension.

Merger Completion: BEST Inc. has completed its merger with Phoenix Global Partners, resulting in BEST becoming a wholly owned subsidiary and ceasing to be publicly traded. Shareholders will receive cash compensation for their shares as outlined in the Merger Agreement.

Delisting from NYSE: Following the merger, BEST Inc. has requested the suspension of trading of its American Depository Shares on the New York Stock Exchange and plans to deregister its securities, effectively ending its reporting obligations under U.S. securities laws.

Merger Completion: Best Inc. has successfully completed its merger with Phoenix Global Partners, resulting in it becoming a wholly owned subsidiary and ceasing to be publicly traded.

Shareholder Approval: The merger was approved by BEST Inc. shareholders, which follows previous notifications of non-compliance from the NYSE regarding financial filing delays amid privatization efforts.

Compliance Issue with NYSE: BEST Inc. has received a notice from the New York Stock Exchange indicating non-compliance with listing requirements due to its failure to timely file semi-annual financial information for the first half of 2024.

Privatization Plans: The company is focusing on a going private transaction, which will result in it becoming privately held and its shares being delisted from the NYSE.

Alibaba's Investment in Ably Corp: Alibaba Group has invested $71.4 million in South Korean apparel brand Ably Corp, making it the first unicorn of 2024 with a valuation exceeding $1 billion, significantly up from its previous valuation of 900 billion won.

Market Impact and Valuation Changes: This investment marks Alibaba's first equity stake in a Korean shopping app, while Ably's valuation has surged to approximately 3 trillion won, reflecting a growing trend in the South Korean startup ecosystem.